Brensocatib AZD-7986
【化學名】Brensocatib
【原研】阿斯利康
【上市時間】臨床三期
【用途】用于治療支氣管擴張癥和新型冠狀病毒感染
Brensocatib AZD-7986
一、產品概述
Brensocatib是由阿斯利康研發(fā)的一種小分子藥物，是一種CTSC抑制劑。目前該藥物最高研發(fā)階段為臨床三期，用于治療支氣管擴張癥和新型冠狀病毒感染。
二、主要產品
Description | Structural Formula | CAS No. | Category |
Brensocatib |  | 1802148-05-5 | API |
5-chloro-3-methylbenzo[d]oxazol-2(3H)-one |
| 5790-90-9 | intermediates |
tert-butyl (S)-(1-amino-3-(4-bromophenyl)-1-oxopropan-2-yl)carbamate |
| 869569-99-3 | intermediates |
(S)-4-(tert-butoxycarbonyl)-1,4-oxazepane-2-carboxylic acid |
| 1273567-44-4 | intermediates |
tert-butyl (S)-(1-amino-3-(4-iodophenyl)-1-oxopropan-2-yl)carbamate |
| 868694-44-4 | intermediates |
3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2(3H)-one |
| 1220696-32-1 | intermediates |
tert-butyl (S)-(1-cyano-2-(4-iodophenyl)ethyl)carbamate |
| 1159489-37-8 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.